Cancer NetworkOriginal article
<![CDATA[OST-HER2 Shows Significant Final 3-Year OS Benefit in Osteosarcoma Trial]]>
Phase 2positiveOST-HER2Positive
AI Analysis
Summary
OST-HER2 demonstrated significant final 3-year overall survival benefit of 72.7% versus 45.8% in historical controls for pulmonary metastatic osteosarcoma in a Phase 2b trial.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Final 3-year OS rate of 72.7% with OST-HER2 vs 45.8% in combined historical control
Importance:7/10
Sentiment:
0.80
oncologyosteosarcomaPhase 2boverall survivalclinical trial data
Read the original article
Published by Cancer Network on October 7, 2026 3:00 PM